158 related articles for article (PubMed ID: 37094084)
1. Intriguing findings on lebrikizumab for treating moderate-to-severe atopic dermatitis.
Arents BWM
Br J Dermatol; 2023 May; 188(6):694. PubMed ID: 37094084
[No Abstract] [Full Text] [Related]
2. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE).
Simpson EL; Flohr C; Eichenfield LF; Bieber T; Sofen H; Taïeb A; Owen R; Putnam W; Castro M; DeBusk K; Lin CY; Voulgari A; Yen K; Omachi TA
J Am Acad Dermatol; 2018 May; 78(5):863-871.e11. PubMed ID: 29353026
[TBL] [Abstract][Full Text] [Related]
3. Lebrikizumab: First Approval.
Keam SJ
Drugs; 2024 Mar; 84(3):347-353. PubMed ID: 38388870
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial.
Guttman-Yassky E; Blauvelt A; Eichenfield LF; Paller AS; Armstrong AW; Drew J; Gopalan R; Simpson EL
JAMA Dermatol; 2020 Apr; 156(4):411-420. PubMed ID: 32101256
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of IL-13: A New Pathway for Atopic Dermatitis [Formula: see text].
Ratnarajah K; Le M; Muntyanu A; Mathieu S; Nigen S; Litvinov IV; Jack CS; Netchiporouk E
J Cutan Med Surg; 2021; 25(3):315-328. PubMed ID: 33350863
[TBL] [Abstract][Full Text] [Related]
6. IL-13 antagonists in the treatment of atopic dermatitis.
Tubau C; Puig L
Immunotherapy; 2021 Mar; 13(4):327-344. PubMed ID: 33430628
[TBL] [Abstract][Full Text] [Related]
7. Novel Therapeutic Approaches and Targets for the Treatment of Atopic Dermatitis.
Pescitelli L; Rosi E; Ricceri F; Pimpinelli N; Prignano F
Curr Pharm Biotechnol; 2021; 22(1):73-84. PubMed ID: 32525769
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.
Blauvelt A; Thyssen JP; Guttman-Yassky E; Bieber T; Serra-Baldrich E; Simpson E; Rosmarin D; Elmaraghy H; Meskimen E; Natalie CR; Liu Z; Xu C; Pierce E; Morgan-Cox M; Garcia Gil E; Silverberg JI
Br J Dermatol; 2023 May; 188(6):740-748. PubMed ID: 36994947
[TBL] [Abstract][Full Text] [Related]
9. Lebrikizumab for Moderate-to-Severe Atopic Dermatitis. Reply.
Silverberg JI; Guttman-Yassky E; Gontijo Lima R
N Engl J Med; 2023 Jun; 388(24):2299-2300. PubMed ID: 37314719
[No Abstract] [Full Text] [Related]
10. Lebrikizumab Monotherapy for the Treatment of Moderate to Severe Atopic Dermatitis.
Kimura N; Ponda P
J Allergy Clin Immunol Pract; 2023 Sep; 11(9):2957-2960. PubMed ID: 37684078
[No Abstract] [Full Text] [Related]
11. Dupilumab in the treatment of moderate-to-severe atopic dermatitis.
Kraft M; Worm M
Expert Rev Clin Immunol; 2017 Apr; 13(4):301-310. PubMed ID: 28165826
[TBL] [Abstract][Full Text] [Related]
12. Dupilumab, A Monoclonal Antibody for Atopic Dermatitis: A Review of Current Literature.
Blakely K; Gooderham M; Papp K
Skin Therapy Lett; 2016 Mar; 21(2):1-5. PubMed ID: 27223113
[TBL] [Abstract][Full Text] [Related]
13. Novel systemic drugs in treatment of atopic dermatitis: results from phase II and phase III studies published in 2017/2018.
Werfel T
Curr Opin Allergy Clin Immunol; 2018 Oct; 18(5):432-437. PubMed ID: 30095475
[TBL] [Abstract][Full Text] [Related]
14. Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.
Smith B; Engel P; Wu JJ
N Engl J Med; 2023 Jun; 388(24):2299. PubMed ID: 37314718
[No Abstract] [Full Text] [Related]
15. Immunotherapy in atopic dermatitis.
Li W; Man XY
Immunotherapy; 2022 Oct; 14(14):1149-1164. PubMed ID: 36046941
[TBL] [Abstract][Full Text] [Related]
16. Results from 1 year of treatment with lebrikizumab for atopic dermatitis.
Br J Dermatol; 2023 May; 188(6):e43. PubMed ID: 37226395
[No Abstract] [Full Text] [Related]
17. The Role of Interleukins 4 and/or 13 in the Pathophysiology and Treatment of Atopic Dermatitis.
Silverberg JI; Kantor R
Dermatol Clin; 2017 Jul; 35(3):327-334. PubMed ID: 28577802
[TBL] [Abstract][Full Text] [Related]
18. Dupilumab for Moderate-to-Severe Atopic Dermatitis.
Vangipuram R; Tyring SK
Skin Therapy Lett; 2017 Nov; 22(6):1-4. PubMed ID: 29091379
[TBL] [Abstract][Full Text] [Related]
19. Atopic dermatitis 2017: where we were 10-15 years ago in psoriasis.
No DJ; Amin M; Egeberg A; Thyssen JP; Wu JJ
J Dermatolog Treat; 2018 Feb; 29(1):100-101. PubMed ID: 28604121
[TBL] [Abstract][Full Text] [Related]
20. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
